Overview

Gender

male

Donald Berry is Professor and founding chair of the Department of Biostatistics of the University of Texas M.D. Anderson Cancer Center. Donald received a Ph.D. in statistics from Yale University and he previously served on the faculties of the University of Minnesota and Duke University.

He has held endowed faculty positions at Duke University and at M.D. Anderson. He has designed and supervised the conduct of many large clinical trials. A principal focus of his research is the use of biomarkers in cancer and other diseases for learning which patients benefit from which therapies, based on genomics and phenotype.

In particular, he has designed and is a co-PI of I-SPY 2 www.ispy2.org and GBM AGILE nbdabiomarkers.org/gbm-agile, Bayesian adaptive platform clinical trials in high-risk early breast cancer and glioblastoma multiforme, respectively, whose goals are matching experimental therapies with patient subsets defined by tumor molecular characteristics.

Through Berry Consultants, LLC he has designed many innovative clinical trials in all therapeutic areas for pharmaceutical and medical device companies and for international consortia.

Donald is the author of books on statistical methodology and over 400 published articles. He serves on the PDQ Screening and Prevention Board of the National Cancer Institute for which he received the National Institutes of Health Award of Merit in 2010.

In 2014 he was named a Thomson Reuters Highly Cited Researcher in Clinical Medicine and listed as one of The World’s Most Influential Scientific Minds in ScienceWatch.com. Donald has been the principal investigator for numerous research grants from the National Institutes of Health and the National Science Foundation.

He is a Fellow of the American Statistical Association and the Institute of Mathematical Statistics.